Atorvastatin vs Simvastatin: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Atorvastatin competitively inhibits HMG-CoA reductase, blocking the mevalonate pathway that synthesizes both cholesterol and CoQ10. This dual-target bottleneck reduces CoQ10 production by 40–50% within the first month — the energy molecule your mitochondria need to convert food into cellular fuel. CTD documents 340 gene interactions for atorvastatin, including effects on CYP3A4 enzymes that hydroxylate vitamin D and vitamin K-dependent carboxylation proteins critical for calcium routing into bones rather than arteries.
Atorvastatin has 14% bioavailability with a parent half-life of 14 hours, but active metabolites extend effective HMG-CoA inhibition to 20–30 hours — meaning once-daily dosing provides around-the-clock cholesterol and CoQ10 suppression.
- ✓Longest effective duration among lipophilic statins — morning or evening dosing equally effective
- ✓Most clinical evidence of any statin: ChEMBL documents 368 RCTs across 850,148 patients
- ✓Generic since 2011, making lifelong therapy plus CoQ10 supplementation affordable
- ✓Fewer CTD gene interactions than simvastatin (340 vs 1,257), suggesting a narrower off-target profile
- ✗CYP3A4-dependent metabolism creates drug interaction risks with erythromycin, ketoconazole, and grapefruit
- ✗FAERS logs 172,934 adverse event reports with 78.8% classified as serious
- ✗14% bioavailability means 86% of each dose undergoes first-pass hepatic extraction — potentially concentrating depletion effects in the liver
- ✗Higher protein binding (98%) limits dose flexibility and increases accumulation risk with renal impairment
Patients needing high-intensity lipid lowering with stable once-daily dosing, who are not taking CYP3A4-interacting medications and can maintain consistent CoQ10 supplementation.
Simvastatin is a prodrug — the lactone form is converted to its active hydroxy acid in the liver, then inhibits HMG-CoA reductase through the same mevalonate pathway as atorvastatin. CTD documents a striking 1,257 gene interactions for simvastatin, nearly four times atorvastatin's count, reflecting a broader molecular footprint that includes not just cholesterol and CoQ10 synthesis genes but also inflammatory, apoptotic, and immune signaling pathways. The same mevalonate blockade depletes CoQ10, impairs vitamin D activation, and reduces vitamin K2-dependent protein carboxylation.
Simvastatin has only 5% oral bioavailability with a short 4.85-hour half-life, requiring evening dosing to align peak activity with the body's overnight cholesterol synthesis cycle for maximum LDL reduction.
- ✓One of the oldest and cheapest generic statins — maximizing budget for supplementation
- ✓ChEMBL documents 330 RCTs across 588,308 patients, including the landmark 4S and HPS trials
- ✓Short half-life means faster clearance if side effects develop — CoQ10 levels recover more quickly after discontinuation
- ✓Lower protein binding (95% vs 98%) may slightly reduce drug accumulation in some patients
- ✗1,257 CTD gene interactions — 3.7x more than atorvastatin — indicate broader systemic metabolic disruption
- ✗Strict evening-only dosing requirement due to short 4.85-hour half-life
- ✗FDA boxed warning against 80 mg dose due to elevated myopathy risk (the CoQ10-depletion muscle damage pathway)
- ✗FAERS logs 116,580 adverse event reports with a 13.1% death-associated rate
Cost-conscious patients with moderate cardiovascular risk who can reliably take evening doses and don't need the maximum LDL reduction that atorvastatin provides.
Feature Comparison
| Feature | Atorvastatin | Simvastatin |
|---|---|---|
| Drug Class | HMG-CoA reductase inhibitor (lipophilic) | HMG-CoA reductase inhibitor (lipophilic prodrug) |
| Nutrients Depleted | 3 — CoQ10, vitamin D, vitamin K2 | 3 — CoQ10, vitamin D, vitamin K2 |
| CTD Gene Interactions | 340 documented | 1,257 documented |
| Bioavailability | 14% | 5% |
| Half-Life | 14 hours (active metabolites 20–30 h) | 4.85 hours |
| FAERS Reports | 172,934 (78.8% serious) | 116,580 (13.1% death-associated) |
| Dosing Flexibility | Morning or evening | Evening only |
| Max LDL Reduction | ~55% at 80 mg | ~40% at 40 mg (80 mg restricted) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both statins deplete the same three nutrients through identical mevalonate pathway inhibition — your CoQ10, vitamin D, and K2 supplementation plan is the same for either drug. The pharmacological differences matter more. Atorvastatin delivers stronger LDL reduction (55% vs 40%), flexible dosing, and a narrower gene interaction profile (340 vs 1,257 in CTD). Simvastatin costs less and clears faster, but its 1,257 gene interactions, FDA-restricted maximum dose, and evening-only timing make it the more demanding choice to manage. FAERS data adds context: simvastatin carries a 13.1% death-associated rate across 116,580 reports versus atorvastatin's 10.8% across 172,934 reports. For most patients, atorvastatin's combination of potency, dosing flexibility, and narrower molecular footprint makes it the stronger default — but simvastatin remains a solid option when cost is the primary constraint.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 340 gene interactions for atorvastatin, 1,257 gene interactions for simvastatin including inflammatory and apoptotic pathway genes
- [2]ChEMBL bioactivity database: 368 RCTs for atorvastatin (850,148 patients), 330 RCTs for simvastatin (588,308 patients)
- [3]FAERS (FDA Adverse Event Reporting System): 172,934 atorvastatin reports (78.8% serious, 10.8% death-associated), 116,580 simvastatin reports (13.1% death-associated)
- [4]PharmGKB pharmacogenomics database: SLCO1B1 Level 1A evidence for statin myopathy risk; CYP3A4 metabolism annotations for both drugs
- [5]PubMed PMID 22085343 — FDA Drug Safety Communication: new restrictions and dose limitations for simvastatin (Zocor) to reduce risk of muscle injury. 2011
Check your medications
Check Free →